Latest News

New clinical trial results show LT3001's promise in treating acute ischemic stroke, demonstrating safety and improved patient outcomes without complications.

The associate professor of physical medicine and rehabilitation at Virginia Commonwealth University discussed his passion for educating others about electrodiagnosis and ultrasound in neuromuscular disorders.

A physician assistant who specializes in neurology previewed her upcoming presentation on evaluating patients with headache at the 2025 Baptist Miami Neuroscience Symposium.

A phase 3 study evaluates remibrutinib's safety and efficacy for generalized myasthenia gravis, promising new treatment options for patients.

A phase 1/2 trial explores YTB323, a CAR T cell therapy, for treating generalized myasthenia gravis, aiming to enhance patient outcomes and safety.

A phase 3 study will evaluate iptacopan's efficacy in treating generalized myasthenia gravis, focusing on daily living activities and safety outcomes.

UCB's Kygevvi becomes the first FDA-approved treatment for thymidine kinase 2 deficiency, offering hope to patients with this rare neuromuscular disorder.

Gregory Hawryluk, MD, PhD, a neurosurgeon at Cleveland Clinic, spoke on the development and clinical impact of new global guidelines for penetrating traumatic brain injury.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the 2025 AANEM Annual Meeting!

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 31, 2025.

Salvia BioElectronics’ PRIMUS system, currently being assessed in a clinical trial, delivers subcutaneous occipital and supraorbital nerve stimulation for patients with resistant migraine.

Avi Singh Gandh, MD, neurology resident at Emory University School of Medicine, reflected on how modern neurology can help interpret the Salem witch trials.